Loomis Sayles & Co. L P Purchases 78,708 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Loomis Sayles & Co. L P increased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 15.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 578,024 shares of the company's stock after acquiring an additional 78,708 shares during the quarter. Loomis Sayles & Co. L P owned about 1.20% of Mirum Pharmaceuticals worth $23,901,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Jones Financial Companies Lllp increased its holdings in shares of Mirum Pharmaceuticals by 100.0% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after acquiring an additional 357 shares during the period. R Squared Ltd purchased a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at approximately $69,000. AlphaQuest LLC increased its holdings in shares of Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after purchasing an additional 1,658 shares during the period. Avanza Fonder AB acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth about $189,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Mirum Pharmaceuticals during the third quarter worth about $215,000.

Insider Activity at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 27,279 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $1,206,004.59. Following the completion of the sale, the chief executive officer now owns 138,641 shares of the company's stock, valued at $6,129,318.61. This trade represents a 16.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Jolanda Howe sold 750 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the sale, the senior vice president now owns 2,926 shares of the company's stock, valued at approximately $125,291.32. This represents a 20.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 133,679 shares of company stock worth $6,007,081 in the last three months. 22.87% of the stock is owned by company insiders.

Mirum Pharmaceuticals Stock Up 2.5 %

NASDAQ MIRM traded up $1.11 during trading hours on Wednesday, reaching $45.15. 93,233 shares of the company traded hands, compared to its average volume of 518,232. The stock has a market capitalization of $2.21 billion, a PE ratio of -22.38 and a beta of 1.04. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $54.23. The company has a 50 day moving average of $47.89 and a two-hundred day moving average of $43.93. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. As a group, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on MIRM shares. HC Wainwright increased their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research note on Thursday, February 27th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of "Buy" and an average target price of $58.20.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.